ARCH THERAPEUTICS, INC.: 10-Q filed 2012-05-03

Name: ARCH THERAPEUTICS, INC.: 10-Q filed 2012-05-03
Creator: ARCH THERAPEUTICS, INC.

What ARCH THERAPEUTICS, INC. reported in its quarterly report filed 2012-05-03 (fiscal Q2 2012): 14 published measures, 59 facts as tagged in accession 0001165527-12-000396.

This filing

Form: 10-Q (quarterly report)
Filed: 2012-05-03
Fiscal period: fiscal Q2 2012
Accession: 0001165527-12-000396 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All ARCH THERAPEUTICS, INC. filings.

Reported measures

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

Period	Value	Unit	Days
At 2012-03-31	4,987	USD
At 2011-09-30	14,963	USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

Period	Value	Unit
At 2012-03-31	5,048	USD
At 2011-12-31	14,156	USD
At 2011-09-30	17,925	USD
At 2011-03-31	0	USD
At 2010-12-31	0	USD
At 2010-09-30	0	USD
At 2009-09-15	0	USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

Period	Value	Unit	Days
2012-01-01 to 2012-03-31	-9,108	USD	91
2011-10-01 to 2012-03-31	-9,976	USD	183
2009-09-16 to 2012-03-31	-15,013	USD	928
2011-01-01 to 2011-03-31	0	USD	90
2010-10-01 to 2011-03-31	0	USD	182

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

Period	Value	Unit	Days
2012-01-01 to 2012-03-31	-9,108	USD	91
2011-10-01 to 2012-03-31	-12,877	USD	183
2009-09-16 to 2012-03-31	-15,013	USD	928
2011-01-01 to 2011-03-31	0	USD	90
2010-10-01 to 2011-03-31	0	USD	182

Revenue

Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.

Period	Unit	Days
2012-01-01 to 2012-03-31	USD	91
2011-10-01 to 2012-03-31	USD	183
2009-09-16 to 2012-03-31	USD	928
2011-01-01 to 2011-03-31	USD	90
2010-10-01 to 2011-03-31	USD	182

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

Period	Value	Unit	Days
2012-01-01 to 2012-03-31	0	USD	91
2011-10-01 to 2012-03-31	0	USD	183
2009-09-16 to 2012-03-31	20,061	USD	928
2011-01-01 to 2011-03-31	0	USD	90
2010-10-01 to 2011-03-31	0	USD	182

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

Period	Value	Unit	Days
2012-01-01 to 2012-03-31	4,000,000	shares	91
2011-10-01 to 2012-03-31	4,000,000	shares	183
2011-01-01 to 2011-03-31	0	shares	90
2010-10-01 to 2011-03-31	0	shares	182

Income tax expense or benefit

Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.

Period	Unit	Days
2012-01-01 to 2012-03-31	USD	91
2011-10-01 to 2012-03-31	USD	183
2009-09-16 to 2012-03-31	USD	928
2011-01-01 to 2011-03-31	USD	90
2010-10-01 to 2011-03-31	USD	182

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

Period	Value	Unit	Days
At 2012-03-31	5,048	USD
At 2011-09-30	18,024	USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

Period	Value	Unit	Days
At 2012-03-31	61	USD
At 2011-09-30	3,061	USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

Period	Value	Unit	Days
2012-01-01 to 2012-03-31	9,108	USD	91
2011-10-01 to 2012-03-31	9,976	USD	183
2009-09-16 to 2012-03-31	15,013	USD	928
2011-01-01 to 2011-03-31	0	USD	90
2010-10-01 to 2011-03-31	0	USD	182

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

Period	Value	Unit	Days
At 2012-03-31	16,000	USD
At 2011-09-30	16,000	USD

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

Period	Value	Unit	Days
2012-01-01 to 2012-03-31	9,108	USD	91
2011-10-01 to 2012-03-31	9,976	USD	183
2009-09-16 to 2012-03-31	15,013	USD	928
2011-01-01 to 2011-03-31	0	USD	90
2010-10-01 to 2011-03-31	0	USD	182

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

Period	Value	Unit	Days
2012-01-01 to 2012-03-31	0	USD	91
2011-10-01 to 2012-03-31	0	USD	183
2009-09-16 to 2012-03-31	20,000	USD	928
2011-01-01 to 2011-03-31	0	USD	90
2010-10-01 to 2011-03-31	0	USD	182

Inspect the source

Entity: ARCH THERAPEUTICS, INC. / CIK 0001537561
Captured: 2026-09-22 19:51 UTC
SEC response SHA-256: 63d0e84748ee59ab7c6817be68d0a32b23d83273213bc50081bb86253a1d4cc2

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python

import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001537561.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))